CC-97540
Phase 2Small molecule
CC-97540 is one of 101 small molecule programs targeting NMOSD. It is currently in Phase 2.
4
Indications
6
Total Trials
5
Active Trials
100
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
145 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Versed
CConrado Roberto Hoffmann Filho
Phase 3
Frexalimab
SanofiPhase 3
Clemastine Fumarate
NovartisPhase 3
Activated Charcoal
SanofiPhase 3
Mayzent
NovartisPhase 3
Antihistamine
Arrowhead PharmaceuticalsPhase 3
MRI Contrast-Enhancing Agents
SanofiPhase 3
Tolebrutinib
SanofiPhase 3
PBR06
UUniversity Hospital, Bordeaux
Phase 3
CC-97540
JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma1 trial
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis1 trial
Multiple Sclerosis1 trial
A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants With Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG).
Active, not recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT06220201·120 enrolled
Systemic Lupus Erythematosus1 trial
A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1)
Active, not recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT05869955·270 enrolled
Lupus Erythematosus, Systemic1 trial
A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
Active, not recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 2·NCT07015983·89 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CC-97540. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details